Tethys to push diabetes risk test with $25m
This article was originally published in Clinica
Executive Summary
Tethys Bioscience is to ramp up commercialisation of its diabetes risk test, PreDx, after raising $25m in a series B financing round. Lead investor in the round was aeris CAPITAL; other participants in the fundraising include Tethys' existing shareholders and new investor Wasatch Advisors.